These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18239808)

  • 1. Analysis of antibiotic resistance markers in Chlamydia trachomatis clinical isolates obtained after ineffective antibiotic therapy.
    Shkarupeta MM; Lazarev VN; Akopian TA; Afrikanova TS; Govorun VM
    Bull Exp Biol Med; 2007 Jun; 143(6):713-7. PubMed ID: 18239808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibacterial therapy of Chlamydia trachomatis infections].
    Sidorenko SV
    Antibiot Khimioter; 2001; 46(2):3-9. PubMed ID: 11544749
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic approaches to Chlamydia infections.
    Senn L; Hammerschlag MR; Greub G
    Expert Opin Pharmacother; 2005 Oct; 6(13):2281-90. PubMed ID: 16218888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urogenital infections linked to Chlamydia and mycoplasmas].
    Fourmaux S; Bebear C
    Prog Urol; 1997 Feb; 7(1):132-6. PubMed ID: 9116732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-day Azithromycin Treatment Regimen for Mycoplasma genitalium Infection Also Effectively Eradicates Chlamydia trachomatis.
    Unemo M; Endre KM; Moi H
    Acta Derm Venereol; 2015 Jul; 95(6):730-2. PubMed ID: 25823977
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides.
    Misyurina OY; Chipitsyna EV; Finashutina YP; Lazarev VN; Akopian TA; Savicheva AM; Govorun VM
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1347-9. PubMed ID: 15047540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection.
    Shao L; You C; Cao J; Jiang Y; Liu Y; Liu Q
    Int J Infect Dis; 2020 Jul; 96():121-127. PubMed ID: 32173573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.
    Benamri I; Azzouzi M; Sanak K; Moussa A; Radouani F
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):59. PubMed ID: 34479551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate.
    Ljubin-Sternak S; Mestrovic T; Vilibic-Cavlek T; Mlinaric-Galinovic G; Sviben M; Markotic A; Skerk V
    Folia Microbiol (Praha); 2013 Sep; 58(5):361-5. PubMed ID: 23271498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in the treatment of Chlamydia trachomatis infection].
    Shi LL; Lu JC; Huangfu YM
    Zhonghua Nan Ke Xue; 2005 Apr; 11(4):296-8. PubMed ID: 15921264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolide and fluoroquinolone resistance is uncommon in clinical strains of Chlamydia trachomatis.
    Deguchi T; Hatazaki K; Ito S; Kondo H; Horie K; Nakane K; Mizutani K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M
    J Infect Chemother; 2018 Aug; 24(8):610-614. PubMed ID: 29627327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection.
    Horner P
    Sex Transm Infect; 2006 Aug; 82(4):340-3. PubMed ID: 16877590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of Chlamydia tracomatis pelvic infection].
    Van den Brûle F; Freyens A; Gaspard U
    Rev Med Liege; 2006; 61(5-6):433-41. PubMed ID: 16910273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of genital Chlamydia trachomatis infections.
    Drug Ther Bull; 1994 Nov; 32(11):87-8. PubMed ID: 7635012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlamydia trachomatis infections in children.
    Wilkowska-Trojniel M; Ostaszewska-Puchalska I; Zdrodowska-Stefanow B
    Med Wieku Rozwoj; 2005; 9(1):71-81. PubMed ID: 16082068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of mutation in macrolide resistance genes in Chlamydia trachomatis clinical isolates with decreased susceptibility to azithromycin.
    Bhengraj AR; Srivastava P; Mittal A
    Int J Antimicrob Agents; 2011 Aug; 38(2):178-9. PubMed ID: 21570258
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections].
    Chulig I
    Antibiot Khimioter; 1996 Feb; 41(2):14-5. PubMed ID: 8929112
    [No Abstract]   [Full Text] [Related]  

  • 18. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
    J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urogenital chlamydia infection: treatment with wilprafen].
    Iakubovich AI; Chuprin AE; Rakitin DA
    Urologiia; 2003; (1):55-8. PubMed ID: 12621971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The evaluation of the detection of lower urogenital infections by Chlamydia trachomatis in France (Part II) (February 2003)].
    ANAES Service d'Evaluation des Technologies and Service d'Evaluation Economique
    Gynecol Obstet Fertil; 2004 Jan; 32(1):90-5. PubMed ID: 14736606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.